EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma.
Pharmaceutics. 2019 Oct 1;11(10):504. doi: 10.3390/pharmaceutics11100504.
Pharmaceutics. 2019.
PMID: 31581483
Free PMC article.